---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-326925"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2025-12-19T23:59:59+00:00"
generated_at: "2026-05-16T12:35:00.086137+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma raises ~$10M in dilutive public offering; cash runway through Q1 2027

## Summary
- Gross proceeds ~$10M from 35.7M shares/pre-funded warrants and 17.9M warrants at $0.28 combined offering price.
- Net proceeds ~$8.9M (~$10.3M if underwriters exercise full option), after underwriting discounts and expenses.
- Cash runway extended into Q1 2027 based on net proceeds, existing cash, and expected $10M from ImmunoScape collaboration.
- Underwriters have 30-day option to purchase up to 5,357,140 additional shares and 2,678,570 warrants.

## SEC filing metadata
- accession: 0001193125-25-326925
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2025-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312525326925/0001193125-25-326925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312525326925/d213128d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-326925
- JSON: https://secwatch.observer/filing/0001193125-25-326925.json
- Plain text: https://secwatch.observer/filing/0001193125-25-326925.txt

## Key facts
- Material Agreements
  Cue Biopharma, Inc. entered into Underwriting Agreement with H.C. Wainwright & Co., LLC (effective 2025-12-19).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: H.C. Wainwright & Co., LLC
  - Effective: 2025-12-19
  source text: On December 19, 2025, Cue Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312525326925/0001193125-25-326925-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.